All In MedTech

Device Trial Radar · NCT04816591

Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 376 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

376

Actual

Start

May 27, 2021

Primary completion

Aug 15, 2024

Study completion Mar 26, 2025

Sponsor

Lead sponsor
Cerenovus, Part of DePuy Synthes Products, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Mar 25, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multi-center, open-label, randomized controlled study in which subjects can receive standard of care (SOC) alone or SOC and TRUFILL n-BCA MMA embolization for the treatment of chronic subdural hematomas (cSDH).

Conditions

  • Chronic Subdural Hematoma

Interventions

  • Experimental: Interventional Cohort: TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic SystemDevice

    Standard of Care Surgery + Embolization

  • Standard of Care SurgeryOther

    Standard of Care Surgery Only

  • Experimental: Interventional Cohort: TRUFILL n-BCA Liquid Embolic SystemDevice

    Standard of Care Medical Management + Embolization

  • Standard of Care Medical ManagementOther

    Standard of Care Medical Management Only

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Residual or Re-accumulation of the Chronic Subdural Hematoma (cSDH) (Greater Than [>] 10 Millimeter [mm]) as Assessed by an Independent Core Laboratory OR Any Re-operation or Surgical Procedure on the cSDH at 6 MonthsTime frame: At 6 months
  2. Percentage of Participants With All Adverse Events (AEs)Time frame: From randomization up to 6 months

Locations

33 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Carondelet St Joseph's Hospital

    Tucson, Arizona

  • John Muir Physician Network Clinical Research Center

    Walnut Creek, California

30 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.